Pharma BD Deal Intelligence
Gilead's $1.2B NASH bet from Nimbus Apollo ended in a fully empty fibrotic-disease pipeline by 2025 — a near-total loss.
Full analysis, sources & comparables →Gilead will acquire the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics for $400 million up front and up to $800 million in development milestones.
Nimbus inked 'a remarkable $400 million upfront' deal with Gilead for NASH, positioning the company favorably for subsequent fundraising.
NIDDK estimates about 24% of US adults have NAFLD/MASLD and about 1.5%-6.5% of US adults have NASH/MASH, with broader estimates of 9-15 million adults affected.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead acquired Nimbus Apollo Inc. (a wholly-owned subsidiary of Nimbus Therapeutics) and its ACC inhibitor program targeting NASH. Nimbus received $400M upfront with up to $800M in additional development milestones. Lead asset NDI-010976 (later firsocostat) became central to Gilead's NASH combination strategy.
Gilead's $1.2B NASH bet from Nimbus Apollo ended in a fully empty fibrotic-disease pipeline by 2025 — a near-total loss.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) (this deal) | 2016 | $1.2B | 20 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2016 deals · Gilead Sciences Inc. deals · Infectious Disease deals